Evidence map›Paper›PMID 41203648›Full record

ArticleNPJ breast cancer2025

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Mengqian Ni, Daining Wang, Shu Dun, Qingru Zhou, Wen Xia, Ruoxi Hong, Yanxia Shi, Zhongyu Yuan, Jiajia Huang, Fei Xu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mengqian Ni *Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Daining Wang *Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Shu DunDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Qingru ZhouDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Wen XiaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Ruoxi HongDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Yanxia ShiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Zhongyu YuanDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Jiajia HuangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Fei XuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Lixia LiCancer Hospital, Affiliated Hospital of Guangdong Medical University, Zhanjiang, P.R. China.
Yabing CaoDepartment of Oncology, Kiang Wu Hospital, Macau, P.R. China.
Danmei PangDepartment of Medical Oncology, Foshan First People's Hospital, Foshan, P.R. China.
Shusen WangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. wangshs@sysucc.org.cn.
Xin AnDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China. anxin@sysucc.org.cn.

Funding

National Key Research and Development Program, National Natural Science Foundation of China 2021YFE0206300
6 · The paper itself

Abstract

This real-world, multicenter study evaluated trastuzumab deruxtecan (T-DXd) in 64 patients with HR-negative, HER2-low metastatic breast cancer between May 2022 and May 2025. The median lines of therapy were 3 (range 1-7). The objective response rate (ORR) was 35.9%, and the disease control rate was 75%. Median real-world progression-free survival (rwPFS) and overall survival were 5.0 months and 14.9 months, respectively. Multivariate analysis identified brain metastases and prior Trop-2 ADC treatment as independent predictors of shorter rwPFS. The most common adverse events were nausea (71.9%), fatigue (39.1%), anorexia (31.3%), and neutropenia (31.3%). Grade 3/4 adverse events were primarily neutropenia (9.4%), thrombocytopenia (7.8%), and nausea (3.1%). Despite lower ORRs in patients with BRCA1 mutations or MYC amplifications, the differences were not statistically significant. This study confirms the clinical efficacy and manageable safety profile of T-DXd in this population, identifying high-risk subgroups and potential resistance biomarkers to inform treatment decisions.

Identifiers

PMID41203648
PMCPMC12594972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.